CJC-1295 No DAC + Ipamorelin Multi-Compound Research Formulation
Is GHK-Cu FDA-approved
Why this matters: injectable GLP-1s like semaglutide and tirzepatide achieve 15 to 20% weight reductions, but injections, cost, and adherence limit real-world use (Santulli review, Journal of Diabetes & Metabolic Disorders, 2025)
In some embodiments, the otic formulation or composition comprises between about 0.01% to about 3% by weight of the carbomer
Hyperglycemia Risk: On the other hand, certain alcoholic beverages, especially those with high sugar content, can spike blood glucose levels
Reconstitute 3 mL BAC water Concentration 23.3 mg/mL total blend Daily draw 10 units = 0.10 mL = ~2.33 mg total Typical cycle 4-6 weeks Pre-Blended GLOW Vial Overview The 5:1:1 blend is GHK-Cu-heavy by weight